Published in J Virol on July 24, 2013
Influenza virus M2 protein has ion channel activity. Cell (1992) 8.52
The molecular basis of the specific anti-influenza action of amantadine. EMBO J (1985) 7.08
ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). Science (1964) 6.72
Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell (2010) 4.33
The M2 proton channels of influenza A and B viruses. J Biol Chem (2005) 3.49
Unpacking the incoming influenza virus. Cell (1992) 3.24
Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol (2002) 2.97
Transport of incoming influenza virus nucleocapsids into the nucleus. J Virol (1991) 2.92
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov (2008) 2.36
Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci (2000) 2.23
The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol (2005) 2.23
The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol (2006) 2.07
The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. J Cell Biol (1996) 1.83
Avian influenza: a new pandemic threat? Mayo Clin Proc (2004) 1.67
The molecular mechanism of action of the proton ionophore FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone). Biophys J (1983) 1.53
Proton transport through influenza A virus M2 protein reconstituted in vesicles. Biophys J (2007) 1.47
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry (2009) 1.47
A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc Natl Acad Sci U S A (2000) 1.45
Membrane permeability changes at early stages of influenza hemagglutinin-mediated fusion. Biophys J (2003) 1.43
A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen (2002) 1.43
Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J Am Chem Soc (2011) 1.37
A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J Virol Methods (2001) 1.35
Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc Natl Acad Sci U S A (2013) 1.34
High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol (2004) 1.28
Slow fluorescent indicators of membrane potential: a survey of different approaches to probe response analysis. J Photochem Photobiol B (1996) 1.25
Potential-sensitive molecular probes in membranes of bioenergetic relevance. Biochim Biophys Acta (1990) 1.24
Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One (2011) 1.20
Efficient infection mediated by viral receptors incorporated into retroviral particles. J Virol (1998) 1.14
Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res (2013) 1.11
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science (1997) 1.11
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem (2013) 1.03
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J Med Chem (2011) 1.00
The channel-forming toxin aerolysin neutralizes human immunodeficiency virus type 1. Mol Microbiol (1999) 0.95
Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity. Cell Cycle (2007) 0.95
Kinetics of proton transport into influenza virions by the viral M2 channel. PLoS One (2012) 0.92
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. ACS Med Chem Lett (2011) 0.92
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. J Med Chem (2010) 0.91
Discovery of highly potent agents against influenza A virus. Eur J Med Chem (2010) 0.86
Virus-like particles as quantitative probes of membrane protein interactions. Biochemistry (2008) 0.86
Strategies to identify ion channel modulators: current and novel approaches to target neuropathic pain. Drug Discov Today (2004) 0.84
Negative potentials across biological membranes promote fusion by class II and class III viral proteins. Mol Biol Cell (2010) 0.80
Maturation of the Gag core decreases the stability of retroviral lipid membranes. Virology (2012) 0.77
Blood vessels engineered from human cells. Lancet (2005) 3.61
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32
Ribosome assembly factors prevent premature translation initiation by 40S assembly intermediates. Science (2011) 2.01
Human arteries engineered in vitro. EMBO Rep (2003) 1.51
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
The nucleolar localization domain of the catalytic subunit of human telomerase. J Biol Chem (2002) 1.24
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One (2011) 1.20
Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One (2011) 1.20
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother (2013) 1.18
Function of herpes simplex virus type 1 gD mutants with different receptor-binding affinities in virus entry and fusion. J Virol (2003) 1.18
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J Virol (2012) 1.17
Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA. Acta Crystallogr D Biol Crystallogr (2002) 1.11
Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc (2009) 1.07
A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology (2014) 1.03
Isobaric labeling and tandem mass spectrometry: a novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med (2010) 1.02
Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. J Virol (2011) 0.99
Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A (2013) 0.97
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis (2013) 0.94
Proteomic profiling of amniotic fluid in preterm labor using two-dimensional liquid separation and mass spectrometry. J Matern Fetal Neonatal Med (2008) 0.94
Origin and differential selection of allelic variation at TAS2R16 associated with salicin bitter taste sensitivity in Africa. Mol Biol Evol (2013) 0.90
Torque teno virus (SANBAN isolate) ORF2 protein suppresses NF-kappaB pathways via interaction with IkappaB kinases. J Virol (2007) 0.87
Proportional accumulation of yolk proteins derived from multiple vitellogenins is precisely regulated during vitellogenesis in striped bass (Morone saxatilis). J Exp Zool A Ecol Genet Physiol (2014) 0.86
Virus-like particles as quantitative probes of membrane protein interactions. Biochemistry (2008) 0.86
Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. J Matern Fetal Neonatal Med (2008) 0.85
Ligand-induced architecture of the leptin receptor signaling complex. Mol Cell (2012) 0.84
Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene (2002) 0.84
Cell-free assay of G-protein-coupled receptors using fluorescence polarization. J Biomol Screen (2008) 0.81
The cellular endosomal sorting complex required for transport pathway is not involved in avian metapneumovirus budding in a virus-like-particle expression system. J Gen Virol (2011) 0.78
Nuclear localization of influenza B polymerase proteins and their binary complexes. Virus Res (2011) 0.78
Maturation of the Gag core decreases the stability of retroviral lipid membranes. Virology (2012) 0.77
Application of a split luciferase complementation assay for the detection of viral protein-protein interactions. J Virol Methods (2011) 0.77
In vitro and in vivo replication of influenza A H1N1 WSN33 viruses with different M1 proteins. J Gen Virol (2012) 0.76
Measuring membrane protein interactions using optical biosensors. Methods Mol Biol (2010) 0.75
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight (2017) 0.75